托特罗定联合坦索罗辛治疗留置双J管患者下尿路症状的疗效观察
发布时间：2018-11-24 17:27
【摘要】：目的:观察托特罗定、坦索罗辛以及两药的联合用药治疗留置双J管引起的下尿路症状(LUTS)的疗效。方法:双J管置入术后的患者共80例(男性50例,女性30例),随机分到A、B、C、D四组,每组各20例。所有患者均于术后1周拔除尿管后开始服药,A组给予口服坦索罗辛0.2mg日一次治疗,B组给予口服托特罗定4mg日一次治疗,C组给予口服坦索罗辛0.2mg日一次及托特罗定4mg日一次联合用药治疗,D组为空白对照组,四组均给予相同的术前及术后的常规治疗。所有患者出院后随访3周,3周后返院拔除双J管时填写生活质量评分量表(QOL)、国际前列腺症状评分表(IPSS)及视觉模拟疼痛评分(VAS)。结果:1四组患者的一般资料(年龄、性别、置管方式)在不同组中差异无明显统计学意义(P0.05),各症状评分(IPSS、QOL、VAS)与性别、年龄、置管方式的相关性无明显统计学意义(P0.05)。2 A、B、C、D四组的VAS评分依次为2.43?0.47、2.02?0.43、1.20?0.56、2.87?0.57,多重比较结果显示:坦索罗辛组、托特罗定组和联合用药组治疗效果均优于空白对照组(P0.05),托特罗定联合坦索罗辛组治疗效果优于单一用药组(P0.05),托特罗定组治疗效果优于坦索罗辛组(P0.05)。3 A、B、C、D四组的IPSS评分依次为41.13、43.08、12.63、65.18及QOL评分依次为40.40、36.65、19.70、65.25,多重比较结果显示:托特罗定组与坦索罗辛组对比无显著统计学差异(P0.05),联合用药组治疗效果优于坦索罗辛组、托特罗定组(P0.05)。4 A、B、C、D四组的梗阻症状评分依次为32.13、52.23、18.58、59.08及刺激症状评分依次为51.05、32.95、14.50、63.50,多重比较结果显示:梗阻症状评分中坦索罗辛组、联合用药组治疗效果优于托特罗定组、空白对照组(P0.05),坦索罗辛组与联合用药组差异无明显统计学意义(P0.05),托特罗定组与空白对照组差异无明显统计学意义(P0.05);膀胱刺激症状中托特罗定组、联合用药组治疗效果优于坦索罗辛组、空白对照组(P0.05),托特罗定组与联合用药组差异无明显统计学意义(P0.05),坦索罗辛组与空白对照组差异无明显统计学意义(P0.05)。结论:1托特罗定、坦索罗辛及两药的联合用药均能改善双J管留置术后引起的下尿路症状,且联合用药优于单一用药。2坦索罗辛主要改善双J管置入术后引起的下尿路症状中的尿路梗阻症状,托特罗定主要改善双J管置入术后引起的下尿路症状中的膀胱刺激症状。
[Abstract]:Objective: to observe the efficacy of Todrodine, tamsoloxine and two drugs in the treatment of lower urinary tract (LUTS) caused by indwelling double J tube. Methods: a total of 80 patients (50 males and 30 females) after double J tube implantation were randomly divided into four groups (20 cases in each group). All the patients began to take drugs one week after the removal of urinary catheter. Group A was given once a day of oral tansoroxine 0.2mg and group B was treated with oral tolterodine 4mg once a day. Group C was treated with oral tansoloxine 0.2mg once a day and toterodine 4mg once. Group D was treated as blank control group. All four groups were given the same routine treatment before and after operation. All patients were followed up for 3 weeks after discharge and returned to hospital 3 weeks later to complete the quality of Life scale (IPSS) and Visual Analog pain scale (VAS).) when removing double J tubes. Results: (1) there was no significant difference in the general data (age, sex, catheterization) among the four groups (P0.05). The scores of symptoms (IPSS,QOL,VAS) and gender, age were not significantly different among the four groups (P0.05). There was no significant correlation between catheterization and catheterization (P0.05). 2 the VAS score of group D was 2.43 卤0.47 卤2.020.42 卤0.43 卤1.200.66 卤2.87 / 0.57, respectively. The results of multiple comparison showed that the therapeutic effect of tansoloxine group, toterodine group and combined drug group were better than that of blank control group (P0.05), the effect of tolterodine combined with tamoxoroxine group was better than that of single drug group (P0.05). The therapeutic effect of toterodine group was better than that of tansoloxine group (P0.05). The IPSS score of group D was 41.1383.0812.63n 65.18, and the QOL score of group D was 40.400.36.65,19.70,65.25, respectively. The results of multiple comparison showed that there was no significant difference between toterodine group and tamsoloxine group (P0.05). The therapeutic effect of combined drug group was better than that of tansoroxin group, and that of toterodine group (P0.05). In group D, the score of obstruction symptom was 32.13 ~ 52.23 ~ 18.58 ~ 59.08 and the score of irritation symptom was 51.05 ~ 32.95 ~ 14.50 ~ 63.50 respectively. The therapeutic effect of combined drug group was better than that of tolterodine group, blank control group (P0.05), tamsoloxine group and combined drug group had no significant difference (P0.05). There was no significant difference between tolterodine group and blank control group (P0.05). In the bladder irritation symptoms, the Totterodine group, the combined treatment group was better than the tansoroxine group, the blank control group (P0.05), the Totterodine group and the combined drug group had no significant difference (P0.05). There was no significant difference between tansoroxine group and blank control group (P0.05). Conclusion: (1) the combined use of tolterodine, tamsoloxine and two drugs can improve the symptoms of lower urinary tract after double J tube indwelling. 2 Tansoroxine mainly improved the symptoms of lower urinary tract obstruction caused by double J tube implantation, and Totterodine mainly improved the bladder irritation symptoms of lower urinary tract symptoms after double J tube placement.
【学位授予单位】：河北医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R472
[Abstract]:Objective: to observe the efficacy of Todrodine, tamsoloxine and two drugs in the treatment of lower urinary tract (LUTS) caused by indwelling double J tube. Methods: a total of 80 patients (50 males and 30 females) after double J tube implantation were randomly divided into four groups (20 cases in each group). All the patients began to take drugs one week after the removal of urinary catheter. Group A was given once a day of oral tansoroxine 0.2mg and group B was treated with oral tolterodine 4mg once a day. Group C was treated with oral tansoloxine 0.2mg once a day and toterodine 4mg once. Group D was treated as blank control group. All four groups were given the same routine treatment before and after operation. All patients were followed up for 3 weeks after discharge and returned to hospital 3 weeks later to complete the quality of Life scale (IPSS) and Visual Analog pain scale (VAS).) when removing double J tubes. Results: (1) there was no significant difference in the general data (age, sex, catheterization) among the four groups (P0.05). The scores of symptoms (IPSS,QOL,VAS) and gender, age were not significantly different among the four groups (P0.05). There was no significant correlation between catheterization and catheterization (P0.05). 2 the VAS score of group D was 2.43 卤0.47 卤2.020.42 卤0.43 卤1.200.66 卤2.87 / 0.57, respectively. The results of multiple comparison showed that the therapeutic effect of tansoloxine group, toterodine group and combined drug group were better than that of blank control group (P0.05), the effect of tolterodine combined with tamoxoroxine group was better than that of single drug group (P0.05). The therapeutic effect of toterodine group was better than that of tansoloxine group (P0.05). The IPSS score of group D was 41.1383.0812.63n 65.18, and the QOL score of group D was 40.400.36.65,19.70,65.25, respectively. The results of multiple comparison showed that there was no significant difference between toterodine group and tamsoloxine group (P0.05). The therapeutic effect of combined drug group was better than that of tansoroxin group, and that of toterodine group (P0.05). In group D, the score of obstruction symptom was 32.13 ~ 52.23 ~ 18.58 ~ 59.08 and the score of irritation symptom was 51.05 ~ 32.95 ~ 14.50 ~ 63.50 respectively. The therapeutic effect of combined drug group was better than that of tolterodine group, blank control group (P0.05), tamsoloxine group and combined drug group had no significant difference (P0.05). There was no significant difference between tolterodine group and blank control group (P0.05). In the bladder irritation symptoms, the Totterodine group, the combined treatment group was better than the tansoroxine group, the blank control group (P0.05), the Totterodine group and the combined drug group had no significant difference (P0.05). There was no significant difference between tansoroxine group and blank control group (P0.05). Conclusion: (1) the combined use of tolterodine, tamsoloxine and two drugs can improve the symptoms of lower urinary tract after double J tube indwelling. 2 Tansoroxine mainly improved the symptoms of lower urinary tract obstruction caused by double J tube implantation, and Totterodine mainly improved the bladder irritation symptoms of lower urinary tract symptoms after double J tube placement.
【学位授予单位】：河北医科大学
【学位级别】：硕士
【学位授予年份】：2017
【分类号】：R472
【参考文献】
相关期刊论文 前10条
1 高志远;李陆安;农礼铭;;输尿管腔内扩张并支架内置入治疗输尿管狭窄或肾盂输尿管连接部轻度狭窄的临床应用[J];吉林医学;2016年12期
2 罗钰辉;李颢;龙江;;双J管置入治疗妊娠输尿管结石并发顽固性肾绞痛的疗效观察[J];世界最新医学信息文摘;2016年38期
3 王s，
本文编号：2354478
本文链接：https://www.wllwen.com/linchuangyixuelunwen/2354478.html
最近更新
教材专著
